Our findings leveraging genetic, observational, and molecular epidemiological designs recapitulate insights from preclinical studies indicating a protective effect of ANGPTL4 inhibition in colorectal cancer risk. The gene discussed is ANGPTL4; the disease is colorectal cancer.